Overview

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Status:
Completed

Trial end date:
2020-01-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Espanol de Tumores Neuroendocrinos

Collaborators:

Merck Serono International SA
Pfizer
Threshold Pharmaceuticals

Treatments:

Phosphoramide Mustards
Sunitinib